J Mygatt1, I Sesterhenn2, I Rosner2, Y Chen3, J Cullen4, T Morris-Gore3, J Barton3, A Dobi3, S Srivastava3, D McLeod2, S A Brassell5. 1. Urology Service, Department of Surgery, Walter Reed National Military Medical Center, Bethesda, MD, USA. 2. 1] Urology Service, Department of Surgery, Walter Reed National Military Medical Center, Bethesda, MD, USA [2] Center for Prostate Disease Research, Rockville, MD, USA. 3. Center for Prostate Disease Research, Rockville, MD, USA. 4. 1] Center for Prostate Disease Research, Rockville, MD, USA [2] Uniformed Services, University of the Health Sciences, Bethesda, MD, USA. 5. Urology Service, Mountain States Tumor Institute, Saint Luke's Health Care System, Boise, ID, USA.
Abstract
BACKGROUND: To determine whether prostate cancers detected in the anterior vs posterior zones impact clinicopathological features and patient outcomes. This information could potentially affect clinical management. METHODS: A retrospective pathological review of 1528 radical prostatectomy specimens submitted between 1989 and 2011 was completed. Specimens were characterized as anterior zone vs posterior zone based on index tumor and predominant tumor volume location. The chi-square test was used to determine associations between tumor location and categorical patient features. Kaplan-Meier unadjusted analysis was used to compare biochemical recurrence-free and overall survival. RESULTS: Tumors occurred predominantly in the anterior location in 155 (10.1%) of specimens. There was no difference between mean age, body mass index, racial distribution, family history, number of previous biopsies, clinical Gleason sum or pathological stage in the two groups. Fewer patients had clinically palpable disease in the anterior tumor group, 28.8% vs 40.7% (P=0.0150). Pretreatment PSA was lower in the anterior tumor group. Total tumor volume did differ with anterior tumors having a mean 8.3 cc vs 5.6 cc (P<0.0001) size and a higher incidence of positive margins (P=0.0008). There were no differences in biochemical recurrence-free or overall survival. CONCLUSIONS: Despite the potential for adverse pathological features in anterior-based disease, there appears to be no demographic predilection, notable delay in diagnosis or significant difference in survival outcomes.
BACKGROUND: To determine whether prostate cancers detected in the anterior vs posterior zones impact clinicopathological features and patient outcomes. This information could potentially affect clinical management. METHODS: A retrospective pathological review of 1528 radical prostatectomy specimens submitted between 1989 and 2011 was completed. Specimens were characterized as anterior zone vs posterior zone based on index tumor and predominant tumor volume location. The chi-square test was used to determine associations between tumor location and categorical patient features. Kaplan-Meier unadjusted analysis was used to compare biochemical recurrence-free and overall survival. RESULTS:Tumors occurred predominantly in the anterior location in 155 (10.1%) of specimens. There was no difference between mean age, body mass index, racial distribution, family history, number of previous biopsies, clinical Gleason sum or pathological stage in the two groups. Fewer patients had clinically palpable disease in the anterior tumor group, 28.8% vs 40.7% (P=0.0150). Pretreatment PSA was lower in the anterior tumor group. Total tumor volume did differ with anterior tumors having a mean 8.3 cc vs 5.6 cc (P<0.0001) size and a higher incidence of positive margins (P=0.0008). There were no differences in biochemical recurrence-free or overall survival. CONCLUSIONS: Despite the potential for adverse pathological features in anterior-based disease, there appears to be no demographic predilection, notable delay in diagnosis or significant difference in survival outcomes.
Authors: Christina Sze; Efrat Tsivian; Kae Jack Tay; Ariel A Schulman; Leah G Davis; Rajan T Gupta; Thomas J Polascik Journal: BMC Urol Date: 2019-12-05 Impact factor: 2.264
Authors: J P Radtke; S Boxler; T H Kuru; M B Wolf; C D Alt; I V Popeneciu; S Steinemann; C Huettenbrink; C Bergstraesser-Gasch; T Klein; C Kesch; M Roethke; N Becker; W Roth; H-P Schlemmer; M Hohenfellner; B A Hadaschik Journal: Prostate Cancer Prostatic Dis Date: 2015-06-16 Impact factor: 5.554
Authors: Martin J Magers; Tianyu Zhan; Aaron M Udager; John T Wei; Scott A Tomlins; Angela J Wu; Lakshmi P Kunju; Madelyn Lew; Felix Y Feng; Daniel A Hamstra; Javed Siddiqui; Arul M Chinnaiyan; Jeffrey S Montgomery; Alon Z Weizer; Todd M Morgan; Brent K Hollenbeck; David C Miller; Ganesh S Palapattu; Hui Jiang; Rohit Mehra Journal: Med Oncol Date: 2015-10-06 Impact factor: 3.064
Authors: Athanase Billis; Leandro L L Freitas; Larissa B E Costa; Camila M Angelis; Kelson R Carvalho; Luis A Magna; Ubirajara Ferreira Journal: Int Braz J Urol Date: 2017 Jul-Aug Impact factor: 1.541
Authors: Justin G Mygatt; Jennifer Cullen; Samantha A Streicher; Huai-Ching Kuo; Yongmei Chen; Denise Young; William Gesztes; Grant Williams; Galen Conti; Christopher Porter; Sean P Stroup; Kevin R Rice; Inger L Rosner; Allen Burke; Isabell Sesterhenn Journal: Cancer Med Date: 2020-01-21 Impact factor: 4.452